Staging and prognostic systems: beyond BCLC?
|
|
- Maria Wilkins
- 5 years ago
- Views:
Transcription
1 Staging and prognostic systems: beyond BCLC? Alessandro Vitale, MD, PhD, FEBS U.O.C. di Chirurgia Epatobiliare e dei Trapianti Epatici, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua; Italy
2 ALESSANDRO VITALE, MD, PhD Azienda Ospedaliera e Università di Padova Il sottoscritto dichiara di non aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione e che la presentazione non contiene discussione di farmaci in studio o ad uso off-label alessandro.vitale@unipd.it
3 Importance of HCC prognostic systems (1) Prognosis for individual patients. (2) Common scale for treatment selection for individual patients. Avoiding under and overtreatment. (3) Common scale for the comparison of outcomes among treatment methods and institutions and for RCT design. (4) A graph contrasting outcomes of transplantation to longterm outcomes of preexisting treatment methods for deciding indication of liver transplantation (Transplant benefit). Kudo M, et al. Dig Dis 2011;29:
4 HCC Prognostic Systems 1. PROGNOSTIC SCORES are conventional prognostic scores that incorporate variables that were significant in multivariable (Cox, parametric models) survival analyses. The prognostic weights of the variables are used to construct the score (DATA BASED). 2. STAGING SYSTEMS typically based on systematic reviews of the literature and/or expert opinions (EVIDENCE BASED). These systems stratify the HCC population in evolutionary stages exclusively or mainly defined by tumor characteristics. Farinati F, et al. PLoS Med 2016; 13(4):e
5 Staging and prognostic systems: beyond BCLC? Data based prognostic scores Evidence based staging systems Combined prognostic systems The issue of treatment allocation
6 Data based Prognostic Scores Liu PH, et al. J Hepatol 2016; 64: 601
7 Data based Prognostic Scores OKUDA FRENCH CLIP TOKYO Faria SC, et al. Abdominal Imaging 2014
8 Data based Prognostic Scores Model to Estimate Survival In Ambulatory HCC patients (MESIAH) Yang JD, et al. HEPATOLOGY 2012;56:
9 Data based Prognostic Scores Johnson PJ, et al. JCO 2015; 33: 550 Chan WHA, et al. Liver Int In press
10 Data based Prognostic Scores PRO: objective and reproducible variables and rigorous statistical methodology. Accurate survival prediction CONS: often they are not suitably generalizable to populations different from the one that generated the score, and they don t define tumor stages for treatment selection Farinati F, et al. PLoS Med 2016; 13(4):e
11 Data based Prognostic Scores Staging system (literature based) Prognostic score (multivariate analysis)
12 Staging and prognostic systems: beyond BCLC? Data based prognostic scores Evidence based staging systems Combined prognostic systems The issue of treatment allocation
13 Evidence based staging systems T definition originally refers only to HCC pathological characteristics of patients receiving liver resection There are 3 TNM surgical staging systems: 1) Liver Cancer Study Group of Japan (LCSGJ) 2) American Joint Committee on Cancer (AJCC) and International Union against Cancer(UICC) 3) United Network for Organ Sharing (UNOS) Minagawa M, et al. Ann Surg 2007; 245: 909
14 AJCC-UICC TNM 5th edition, 1997 Evidence based staging systems AJCC-UICC TNM 6th edition, 2002 UNOS TNM, 2002
15 Evidence based staging systems The Barcelona Clinic Liver Cancer (BCLC) Staging Classification for HCC BCLC stage 0 Very early Tumor volume, number and invasiveness Single < 2 cm Carcinoma in situ Performance status Child-Pugh 0 A A Early Single or 3 nodules < 3 cm 0 A B B Intermediate Multinodular 0 A B C Advanced Portal invasion N1M1 1 2 A B D Terminal Any of above > 2 C Cillo U, Vitale A, et al. J Hepatol 2004 Cillo U, Vitale A, et al. J Hepatol 2006
16 Evidence based staging systems PRO: They are useful to link stages to guidelines for the management of patients with HCC and the design of clinical trials. CONS: However, these systems are not based on a strong statistical methodology (variables are not weightened) and they often lack prognostic power Farinati F, et al. PLoS Med 2016; 13(4):e
17 Evidence based staging systems Liu PH, et al. J Hepatol 2016; 64: 601
18 Prognostic pitfalls of BCLC classification ECOG PST 1 classified as BCLC B (in original BCLC stage C) Hsu CY, et al. Hepatology 2013
19 Prognostic pitfalls of BCLC classification Hsu CY, et al. Liver Int In press
20 Evidence based staging systems Prognostic score (multivariate analysis) Staging system (literature based)
21 Staging and prognostic systems: beyond BCLC? Data based prognostic scores Evidence based staging systems Combined prognostic systems The issue of treatment allocation
22 Combined prognostic systems Prognosis Treatment Prognostic score (multivariate analysis) Combined Prognostic System Staging system (literature based)
23 Combined prognostic systems From 2003 Japan TNM poor performance in western patients No PST No AFP Kudo M, et al. Dig Dis 2011;29:
24 Combined prognostic systems 5183 HCC patients (database ITA.LI.CA. - Italian Liver Cancer) Training cohort (3628 pts) / Internal validation cohort (1555 pts) M.F = 3:1 Age (median): 68 yrs Child (median): 6 MELD (median): 11 HCV+ 60%, HBV+ 17%, Alcool 26% Diameter max (median): 3 cm Multifocal: 22% Metastases: 3% BCLC: 0 7%, A 33%, B 12%, C 42%, D 6% Main Treatment: Resection 11%, Transplant 2%, Ablation 30%,TACE 26%, Sorafenib 3%, Other 8%, BSC 20% External validation cohort: 2651 pts (database from Taipei Taiwan, ) Tumor stage classification based on the literature Final score based on multivariate analysis Staging systems did not respect Proportional Hazard Assumption Kaplan-Meier, log-rank test Multivariate log-logistic parametric survival model: ITA.LI.CA staging construction Multivariate log-logistic parametric survival model: comparison between systems Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC)
25 Combined prognostic systems UNOS TNM, 2002 Hong Kong Liver Cancer Staging System BCLC B HCC: Proposal for a Subclassification ITA.LI.CA TUMOR STAGING Variables 0 A B1 B2 B3 C Diameter(cm) < > > 5 > 5 Any Any N nodules > > 3 Any Any Vascular invasion or metastases no no no no no no no no Intra Exta Farinati F, et al. PLoS Med 2016; 13(4):e
26 Combined prognostic systems Farinati F, et al. PLoS Med 2016; 13(4):e
27 Combined prognostic systems Farinati F, et al. PLoS Med 2016; 13(4):e
28 Staging and prognostic systems: beyond BCLC? Data based prognostic scores Evidence based staging systems Combined prognostic systems The issue of treatment allocation
29 HCC Prognostic Factors Patient Prognosis of HCC 1 Most patients have underlying liver disease Key prognostic indicators are not clearly defined Prognostic indicators vary during the course of disease ECOG PS BCLC 4 CUPI 5 Factors affecting HCC prognosis 2,3 Tumour stage Liver function Health status Liver Child- Pugh GRETCH 6 Okuda 7 CLIP 8 JIS 9 TNM Tumour 1. Llovet JM, et al. Lancet 2003;362: Marrero JA, et al. Clin Liver Dis 2006;10: Marrero JA, et al. Hepatology 2005;41: Llovet JM, et al. Semin Liver Dis 1999;19: Leung T, et al. Cancer 2002;94: Chevret S, et al. J Hepatol 1999;31: Schafer DF, et al. Lancet 1999;353: CLIP. Hepatology 1998;28: Makuuchi M, et al. World J Gastroenterol 2006;12:
30 The issue of treatment allocation both the stage and the various types of intervention should ideally be built into the prognostic system.. There are four main factors affecting prognosis: (a) the stage, aggressiveness and growth rate of the tumor; (b) the general health of the patient; (c) the liver function of the patient; and (d) the specific intervention The.. optimal solution would be to develop a prognostic model for each relevant evolutionary stage of the disease (early, intermediate- advanced and terminal) and model into each stage the variables related to each specific intervention.
31 The issue of treatment allocation Bruix J and Sherman M, et al. Hepatology 2005
32 The issue of treatment allocation PROBLEM 1: PROGNOSTIC PROBLEM Pre-determined Staging System Treatment selection Treatment selection Staging System PROBLEM 1: Tumor, liver function, patient related variables differently influence Treatment selection and patient prognosis
33 The issue of treatment allocation PROBLEM 1: PROGNOSTIC PROBLEM?????? Bruix J and Sherman M. Gastroenterology 2016
34 Combined prognostic systems PROBLEM 1: PROGNOSTIC PROBLEM Farinati F, et al. PLoS Med 2016; 13(4):e
35 The issue of treatment allocation PROBLEM 1: PROGNOSTIC PROBLEM 13 points score?? Yau T, et al. Gastroenterology 2014
36 The issue of treatment allocation PROBLEM 1: PROGNOSTIC PROBLEM Yau T, et al. Gastroenterology 2014
37 The issue of treatment allocation PROBLEM 2: THERAPEUTIC PROBLEM Pre-determined Staging System Treatment selection Treatment selection Staging System PROBLEM 2: Treatment selection criteria change with time and should be inclusive (indications better than algorithms)
38 The issue of treatment allocation PROBLEM 2: THERAPEUTIC PROBLEM The tempting simplicity of the BCLC classification came at a price of low clinical utility by compromising the importance of liver transplantation and locoregional therapies in medical management of HCC. Designed using data mostly acquired in small Western patient populations, the BCLC classification lacks universal applicability in terms of discriminatory ability and prognostic accuracy with regard to treatment recommendations. In fact, the BCLC system precludes patients with more advanced disease from receiving radical therapies out of safety considerations. Chapiro J, et al. Nat Rev Gastroenterol Hepatol 2014; 11: 334
39 ?? The issue of treatment allocation PROBLEM 2: THERAPEUTIC PROBLEM????? Bruix J and Sherman M. Gastroenterology 2016
40 The issue of treatment allocation PROBLEM 2: THERAPEUTIC PROBLEM Roayaie S, et al. Hepatology 2015; 62: 440
41 The issue of treatment allocation PROBLEM 2: THERAPEUTIC PROBLEM 1302 BCLC A patients undergoing resection Roayaie S, et al. Hepatology 2015; 62: 440
42 The issue of treatment allocation PROBLEM 2: THERAPEUTIC PROBLEM A total of 3515 treatment-naıve, newly diagnosed HCC patients at a single centre were analyzed Kim KM, et al. Liver Int 2016.
43 The issue of treatment allocation SOLUTION 1: INDEPENDENT ALGORITHM Kudo M, et al. Dig Dis 2011;29:
44 The issue of treatment allocation SOLUTION 2: TREATMENT INDICATIONS Bolondi L, et al. Sem Liv Dis 2012
45 New ITA.LI.CA 2015 database including 6669 HCC patients (database ITA.LI.CA. - Italian Liver Cancer) Inclusion criteria: - Cirrhotic patients - Complete follow-up data - Period Study population: 4867 HCC patients The issue of treatment allocation SOLUTION 3: TREATMENT INDICATIONS+DATA BASED SURVIVAL BENEFIT External validation cohort: 2651 pts (database from Taipei Taiwan, ) ITA.LI.CA treatment indications (no algorithm) were based on: TREATMENT SELECTION as end-point: multivariate logistic regression models SURVIVAL BENEFIT as end-point: multivariate loglogistic parametric survival models Treatment selection and survival benefit were combined using Inverse Probability Weight (IPW) EVIDENCE BASED approach (literature multiple societies document)
46 Variables 0 A B1 B2 B3 C Any Functional score (FS) FS 2: CTP ABandPST 0; CPT 7 and PST 2 FS > 2: CTP C/PST >2 Diameter(cm) < > > 5 > 5 Any Any Any N nodules > > 3 Any Any Any VI / meta no no no no no no no no Intra Extra Any Median survival Therapy LT LR ABL IAT SOR BSC Therapy LT LR ABL IAT SOR BSC Neg Neg Neg Neg Neg 94 5
47 The issue of treatment allocation Variables 0 A B1 B2 B3 C Any Functional score (FS) FS 2: CTP ABandPST 0; CPT 7 and PST 2 FS > 2: CTP C/PST >2 Diameter(cm) < > > 5 > 5 Any Any Any N nodules > > 3 Any Any Any VI / meta no no no no no no no no Intra Extra Any Median survival LIVER TRANSPLANTATION LT ABLATION LIVER RESECTION TACE/TARE SORAFENIB
48 The issue of treatment allocation SOLUTION 3: TREATMENT INDICATIONS+DATA BASE SURVIVAL BENEFIT Following ITA.LI.CA indications: 3153 pts (65%) vs 43% BCLC vs 55% HKLC algorithms In (MS 41 mo) Out (MS 41 mo)
49 CONCLUSIONS There is not worldwide consensus on the best prognostic system for HCC patients The ITA.LI.CA prognostic score showed the best predictive ability in large western and eastern cohorts Beyond BCLC?: - YES, for intrinsicprognosticpitfals(evidencebasedand treatment dependent system) - YES, for treatment relatedpitfals(distancefrom best clinical practice and personalized approach) ITA.LI.CA treatment indications could represent a potential solution??
50 Department of General Surgery and Organ Transplantation, Hepatobiliary Surgery and Liver Transplantation Unit, University Hospital of Padua, Padua; Italy Director: Prof. Umberto Cillo THANK YOU
간암의다양한병기분류법 : 현재사용중인병기분류를중심으로. Kim, Beom Kyung
간암의다양한병기분류법 : 현재사용중인병기분류를중심으로 Kim, Beom Kyung Importance of staging system 환자의예후예측 적절한치료방법적용 ( 수술, 방사선, 항암..) 의료진간의 tumor burden 에대한적절한의사소통 향후연구및 clinical trial 시연구집단의성격에대한객관적기준제시 Requisites for good staging
More informationHepatocellular carcinoma: Intra-arterial treatments
Hepatocellular carcinoma: Intra-arterial treatments Irene Bargellini U.O. Radiologia Interventistica Azienda Ospedaliero Universitaria Pisana IRENE BARGELLINI,MD UO RADIOLOGIA INTERVENTISTICA, AZIENDA
More informationClinical Staging for Hepatocellular Carcinoma: Eastern Perspectives. Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan
Clinical Staging for Hepatocellular Carcinoma: Eastern Perspectives Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan Why is staging system important? Cancer stage can be
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationCelsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging
Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery
More informationUnmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim
Unmet needs in intermediate HCC Korea University Guro Hospital Ji Hoon Kim BCLC HCC Stage 0 PST 0, Child Pugh A Stage A C PST 0 2, Child Pugh A B Stage D PST > 2, Child Pugh C Very early stage (0) 1 HCC
More informationHepatocellular carcinoma: from guidelines to individualized treatment
AISF 2012 Rome, 22-24 February 2012 Hepatocellular carcinoma: from guidelines to individualized treatment A.D. 1088 Luigi Bolondi Professor of Medicine, Chairman Department of Digestive Diseases and Internal
More informationTACE: coming of age?
Invasive procedures in the diagnosis and treatment of liver diseases: focal lesions F.Farinati Gastroenterologia, Padova TACE: coming of age? AISF 2005 TACE: LEVELS OF EVIDENCE Degree of certainty Methodology
More informationAblazione chirurgica e trapianto
Unità di Chirurgia Epatobiliare e Trapianto Epatico Azienda Università di Padova Personalizzazione dell indicazione terapeutica Ablazione chirurgica e trapianto Prof. Umberto Cillo cillo@unipd.it Umberto
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationAlcoholic Liver Disease as First Indication
Alcoholic Liver Disease as First Indication Patrizia Burra Multivisceral Transplant Unit Gastroenterology Department of Surgery, Oncology and Gastroenterology Padua University Hospital, Padua, Italy Patrizia
More informationDiagnostic Procedures. Measurement of Hepatic venous pressure in management of cirrhosis. Clinician s opinion
5 th AISF Post-Meeting Course Diagnostic and Therapeutic Invasive Procedures in Hepatology Rome, February 25 th Diagnostic Procedures Measurement of Hepatic venous pressure in management of cirrhosis Clinician
More informationEASL-EORTC Guidelines
Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according
More informationLiver transplant: what is left after the viruses
Riunione Monotematica A.I.S.F. 2016 The Future of Liver Disease: Beyond HCV is there a Role for Hepatologist? Milan 15 th 2016 Liver transplant: what is left after the viruses Stefano Ginanni Corradini
More informationLiver transplantation: Hepatocellular carcinoma
Liver transplantation: Hepatocellular carcinoma Alejandro Forner BCLC Group. Liver Unit. Hospital Clínic. University of Barcelona 18 de marzo 2015 3r Curso Práctico de Transplante de Órganos Sólidos Barcelona
More informationSurgical management of HCC. Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London
Surgical management of HCC Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London Global distribution of HCC and staging systems WEST 1. Italy (Milan,
More information9th Paris Hepatitis Conference
9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationCHIRURGIA EPATOBILIARE IN WEEK SURGERY?
U.O.C. di Chirurgia Epatobiliare e dei Trapianti Epatici Università degli Studi di Padova CHIRURGIA EPATOBILIARE IN WEEK SURGERY? Umberto Cillo, MD, PhD, FEBS cillo@unipd.it Quali sono gli ingredienti
More informationRESEARCH ARTICLE. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment
DOI:10.22034/APJCP.2017.18.6.1697 RESEARCH ARTICLE Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment Alan Chuncharunee 1,
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationWHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?
WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views
More informationPazienti con Genotipo 1 e Cirrosi Scompensata, pre-/post-olt
Monotematica AISF 2013 Pazienti con Genotipo 1 e Cirrosi Scompensata, pre-/post-olt Pietro Andreone Dipartimento di Scienze Mediche e Chirurgiche Alma Mater Studiorum, Università di Bologna Pisa, 17-19
More informationTREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD
TREATMENT FOR HCC AND CHOLANGIOCARCINOMA Shawn Pelletier, MD Treatment for HCC Treatment strategies Curative first line therapy Thermal ablation vs Resection vs Transplant Other first line therapies TACE
More informationORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:989 994 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Level of -Fetoprotein Predicts Mortality Among Patients With Hepatitis C Related Hepatocellular
More informationINTRODUCTION. Key Words: Carcinoma, hepatocellular; Barcelona Clinic Liver Cancer; Hong Kong Liver Cancer; Neoplasm staging.
Gut and Liver, Vol. 12, No. 1, January 218, pp. 94-11 ORiginal Article Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver
More informationHepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center
Hepatocellular Carcinoma: A major global health problem David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma WORLDWIDE The #2 Cancer Killer Overall cancer
More informationFilippo Schepis, MD Università degli Studi di Modena e Reggio Emilia
Filippo Schepis, MD Università degli Studi di Modena e Reggio Emilia Il sottoscritto dichiara di non aver avuto/di aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationSIRTEX Lunch Symposium, Cebu, 23 Nov Dr. Stephen L. Chan Department of Clinical Oncology The Chinese University of Hong Kong
SIRTEX Lunch Symposium, Cebu, 23 Nov 2013 Dr. Stephen L. Chan Department of Clinical Oncology The Chinese University of Hong Kong I will not talk on Mechanism of SIRT Data on efficacy of SIRT Epidemiology
More informationA) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary), April 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Centre, BC Cancer
More informationAssessment of Liver Function: Implications for HCC Treatment
Assessment of Liver Function: Implications for HCC Treatment A/P Dan Yock Young MBBS, PhD, MRCP, MMed. FAMS Chair, University Medicine Cluster. NUHS Head, Department of Medicine, National University of
More informationInvasive Evaluation of Portal Hypertension. Vincenzo La Mura, MD PhD Department of Biomedical Sciences for Health University of Milan
Invasive Evaluation of Portal Hypertension Vincenzo La Mura, MD PhD Department of Biomedical Sciences for Health University of Milan Vincenzo La Mura, MD, PhD Dipartimento di scienze Biomediche per la
More informationHepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC
Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies
More informationThe Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:
The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: Certified by: Provided by: Endorsed by: Hepatocellular Carcinoma HCC: Age
More informationSurgical resection for hepatocellular carcinoma (HCC)
Surgical resection for hepatocellular carcinoma (HCC) Wojciech G Polak, MD, PhD, FEBS Department of Surgery, Division of HPB and Transplant Surgery, Erasmus MC, University Medical Center Rotterdam the
More informationProfessor Norbert Bräu
Sixth Annual BHIVA Conference for the Management of HIV/Hepatitis Co-Infection in collaboration with BASL and BVHG Professor Norbert Bräu James J Peters VA Medical Center, New York, USA COMPETING INTEREST
More informationTreatment Patterns and Outcomes in Patients With Hepatocellular Carcinoma Stratified by Stage-Guided Treatment Categories
Original Research 987 Treatment Patterns and Outcomes in Patients With Hepatocellular Carcinoma Stratified by Stage-Guided Treatment Categories Kuan-Ling Kuo, PhD a ; David Stenehjem, PharmD a,b ; Frederick
More informationHepatocellular Carcinoma in Qatar
Hepatocellular Carcinoma in Qatar K. I. Rasul 1, S. H. Al-Azawi 1, P. Chandra 2 1 NCCCR, 2 Medical Research Centre, Hamad Medical Corporation, Doha, Qatar Abstract Objective The main aim of this study
More informationHCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros)
HCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros) Yi-Hsiang Huang, MD, Ph.D. Professor, Division of Gastroenterology & Hepatology,
More informationPaul Martin MD FACG. University of Miami
Paul Martin MD FACG University of Miami 1 Liver cirrhosis of any cause Chronic C o c hepatitis epat t s B Risk increases with Male gender Age Diabetes Smoking ~5% increase in HCV-related HCC between 1991-28
More information3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma.
Grant/Research Support - AbbVie, Conatus, Hologic, Intercept, Genfit, Gilead, Mallinckrodt, Merck, Salix, Shire, Vital Therapies Consultant AbbVie, Gilead, Merck Member, Scientific Advisory Board Vital
More informationPrototypes of autoimmune hepatitis and sclerosing cholangitis in childhood
RIUNIONE MONOTEMATICA AISF 2013 Personalizzazione della Cura in Epatologia 17-19 ottobre 2013, PISA Prototypes of autoimmune hepatitis and sclerosing cholangitis in childhood La sottoscritta dichiara di
More information3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice
3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,
More informationAdvances in Systemic Therapy Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016
Advances in Systemic Therapy for Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016 Scope Background Staging and treatment strategies Current systemic therapy
More informationAggressive Treatment of Performance Status 1 and 2 HCC Patients Significantly Improves Survival - an Egyptian Retrospective Cohort Study of 524 Cases
RESEARCH ARTICLE Aggressive Treatment of Performance Status 1 and 2 HCC Patients Significantly Improves Survival - an Egyptian Retrospective Cohort Study of 524 Cases Ashraf Omar Abdel Aziz 1, Dalia Omran
More informationReconsidering Liver Transplantation for HCC in a Era of Organ shortage
Reconsidering Liver Transplantation for HCC in a Era of Organ shortage Professor Didier Samuel Centre Hépatobiliaire Inserm-Paris Sud Research Unit 1193 Departement Hospitalo Universitaire Hepatinov Hôpital
More informationDisclosure. Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report:
Disclosure Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report: Consulting Employment in industry Stockholder of a healthcare company Owner of a healthcare company
More informationSorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience
Journal of the Egyptian National Cancer Institute (2014) 26, 9 13 Cairo University Journal of the Egyptian National Cancer Institute www.nci.cu.adu.eg www.sciencedirect.com Original article Sorafenib for
More informationHepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010
Bronx VA Medical Center Mount Sinai School of Medicine Hepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010 Norbert Bräu, MD, MBA Associate
More informationAdvances in percutaneous ablation for hepatocellular carcinoma
Advances in percutaneous ablation for hepatocellular carcinoma P. Nahon1,2,3 1 Hepatology, Jean Verdier Hospital, APHP, Bondy, France 2 Paris 13 university, Sorbonne Paris Cité, UFRSMBH, Bobigny, France
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationOptimal staging system for predicting the prognosis of patients with hepatocellular carcinoma in China: a retrospective study
Su et al. BMC Cancer (2016) 16:424 DOI 10.1186/s12885-016-2420-0 RESEARCH ARTICLE Open Access Optimal staging system for predicting the prognosis of patients with hepatocellular carcinoma in China: a retrospective
More informationOver the past 20 years, great progress has been made in the
ORIGINAL ARTICLES Staging of Hepatocellular Carcinoma Assessment of the Japanese TNM and AJCC/UICC TNM Systems in a Cohort of 13,772 Patients in Japan Masami Minagawa, MD, PhD,* Iwao Ikai, MD, PhD,* Yutaka
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More informationHCC: Is it an oncological disease? - No
June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -
More informationHow to apply HCC prediction models to practice?
How to apply HCC prediction models to practice? Department of Internal Medicine, Keimyung University School of Medicine Woo Jin Chung HCC prediction models 독특하게간세포암환자들의생존은암의진행상태뿐아니라기저간기능의중증정도에영향을받는특성이있다.
More informationAdvances in percutaneous ablation and systemic therapies for hepatocellular carcinoma
Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma Paris Hepatology Congress 2019 Pierre Nahon Service d Hépatologie Hôpital Jean Verdier Bondy Université Paris 13 INSERM
More informationDeterminants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice
Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice I-Cheng Lee, MD, PhD, Yi-Tzen Chen, RN, Yee Chao, MD, Teh-Ia Huo, MD, Chung-Pin
More informationTowards Precision Medicine in Primary Biliary Cholangitis
Riunione Monotematica A.I.S.F. 2016 THE FUTURE OF LIVER DISEASES: Beyond HCV is there a role for the hepatologist? 14 th October 2016 Towards Precision Medicine in Primary Biliary Cholangitis Marco Carbone,
More informationSEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA
SEQUENCING OF HCC TREATMENT Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA February 2018 DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationStudy Objective and Design
Randomized, Open Label, Multicenter, Phase II Trial of Transcatheter Arterial Chemoembolization (TACE) Therapy in Combination with Sorafenib as Compared With TACE Alone in Patients with Hepatocellular
More informationColangiocarcinoma on the rise!
Colangiocarcinoma on the rise! D. ALVARO, Univ. Sapienza, Rome, Italy. MONOTEMATICA AISF, The future of Liver Diseases, Milano 13-15 Ottobre 2016 Domenico ALVARO, MD. SAPIENZA, ROMA Il sottoscritto dichiara
More informationIl treatment plan nella terapia sistemica dell epatocarcinoma
Il treatment plan nella terapia sistemica dell epatocarcinoma M. Iavarone, MD PhD CRC A.M. e A. Migliavacca Center for the Study of Liver Disease Division of Gastroenterology and Hepatology Fondazione
More informationHepatocellular Carcinoma: Transplantation, Resection or Ablation?
Hepatocellular Carcinoma: Transplantation, Resection or Ablation? Roberto Gedaly MD Chief, Abdominal Transplantation Transplant Service Line University of Kentucky Nothing to disclose Disclosure Objective
More informationSurveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice
Surveillance for Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationONCOLOGY LETTERS 15: , 2018
ONCOLOGY LETTERS 15: 855-862, 2018 Comparison of five staging systems in predicting the survival rate of patients with hepatocellular carcinoma undergoing trans arterial chemoembolization therapy ZHAN
More informationMULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC
Dr Apoorva Gogna MBBS FRCR FAMS Consultant Interventional Radiology Center Department of Diagnostic Radiology SingaporeGeneral Hospital MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC CASE HISTORY
More informationSIRT for Intermediate and Advanced HCC
Pamplona, junio de 2008 SIRT for Intermediate and Advanced HCC Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain 90 Y-RE MRI SPECT FUSION 90 Y-RE = Yttrium-90 radioembolization Sangro
More informationHEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT
HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%
More informationPierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine
Pierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine Il sottoscritto dichiara di non aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione
More informationNIH Public Access Author Manuscript J Surg Res. Author manuscript; available in PMC 2011 May 18.
NIH Public Access Author Manuscript Published in final edited form as: J Surg Res. 2011 April ; 166(2): 189 193. doi:10.1016/j.jss.2010.04.036. Hepatocellular Carcinoma Survival in Uninsured and Underinsured
More informationNomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma
doi: 10.2169/internalmedicine.9064-17 Intern Med Advance Publication http://internmed.jp ORIGINAL ARTICLE Nomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation
More information6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration
Treating : Deciphering the Clinical Data Derek DuBay, MD Associate Professor of Surgery Director of Liver Transplant Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery Liver Regeneration
More informationDue to the disparity between organ availability and
Use of Sorafenib in Patients With Hepatocellular Carcinoma Before Liver Transplantation: A Cost-Benefit Analysis While Awaiting Data on Sorafenib Safety Alessandro Vitale, 1 Michael L. Volk, 2 Davide Pastorelli,
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationRadioembolization: technical aspects
Radioembolization: technical aspects Rita Golfieri Unità Operativa Radiologia Malpighi Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola - Malpighi La sottoscritta dichiara di non aver
More informationRESEARCH ARTICLE. Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.16.6929 Real-Life HCC Treatment - Influence on Outcome of Deviation from Therapy Guidelines RESEARCH ARTICLE Real Life Treatment of Hepatocellular Carcinoma:
More informationTreatment of HCC in real life-chinese perspective
Treatment of HCC in real life-chinese perspective George Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond), FAASLD (US) Chairman Humanity and Health Medical Group, Hong Kong SAR, CHINA
More informationTREATMENT ALGORITHM FOR HEPATOCELLULAR CARCINOMA
HCC treatment : A permanent challenge! TREATMENT ALGORITHM FOR HEPATOCELLULAR CARCINOMA Michel Ducreux, MD, PhD Paul Brousse University Hospital Gustave Roussy Institute Villejuif, FRANCE A low level of
More informationOriginal Article. Comparison of 7 staging systems in north Indian cohort of hepatocellular carcinoma
Tropical Gastroenterology 2010;31(4):271 278 Original Article Comparison of 7 staging systems in north Indian cohort of hepatocellular carcinoma *Sanjay Sarma 1, *Balkrishan Sharma 1, Yogesh Kumar Chawla
More informationRole of Nutritional Support in the Treatment of Alcoholic Liver Disease
Riunione Monotematica AISF Alcoholic Liver Disease: The New Challenge Roma, 4-6 Ottobre 2017 Role of Nutritional Support in the Treatment of Alcoholic Liver Disease Esmeralda Capristo Divisione di Patologie
More informationScreening for HCCwho,
Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology
More informationPercutaneous ablation: indications, techniques and results
Percutaneous ablation: indications, techniques and results Giovan Giuseppe Di Costanzo Dipartimento dei Trapianti UOSC Epatologia AORN A Cardarelli - Napoli Treatment algorithm EASL, EORTC guidelines HCC
More informationLatest Developments in the Treatment of Hepatocellular Carcinoma
Latest Developments in the Treatment of Hepatocellular Carcinoma Roniel Cabrera, MD MS Associate Professor of Medicine Director of Hepatology and Medical Director of Liver Transplantation Division of Gastroenterology,
More informationIl Tumore del Fegato Prospettive Future nel Trattamento dei Tumori Gastrointestinali
Il Tumore del Fegato Prospettive Future nel Trattamento dei Tumori Gastrointestinali Lorenza Rimassa Medical Oncology Unit Humanitas Cancer Center Humanitas Research Hospital Rozzano (Milano) Disclosures
More informationNegative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma
Li et al. World Journal of Surgical Oncology (2015) 13:294 DOI 10.1186/s12957-015-0713-4 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Negative impact of low body mass index on liver cirrhosis
More informationTreatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study
Published online: September 16, 2017 Original Paper Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study Clarence
More informationAclinical staging system for cancer patients provides
Validation of a New Prognostic Staging System for Hepatocellular Carcinoma: the JIS Score Compared With the CLIP Score Masatoshi Kudo, 1 Hobyung Chung, 1 Seiji Haji, 2 Yukio Osaki, 3 Hiroko Oka, 4 Toshihito
More informationNexavar in advanced HCC: a paradigm shift in clinical practice
Nexavar in advanced HCC: a paradigm shift in clinical practice Tim Greten Hanover Medical School, Germany Histopathological progression and molecular features of HCC Chronic liver disease Liver cirrhosis
More informationUsing nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage C hepatocellular carcinoma
Hsu et al. BMC Cancer (2018) 18:289 https://doi.org/10.1186/s12885-018-4202-3 RESEARCH ARTICLE Using nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage
More informationHIV and Hepatocellular Carcinoma. Dr Kosh Agarwal Institute of Liver Studies King s College Hospital Rome May 2013
HIV and Hepatocellular Carcinoma Dr Kosh Agarwal Institute of Liver Studies King s College Hospital Rome May 2013 1 In theory, there is no difference between theory and practice In practice there is Chuck
More informationStatus of hepatocellular carcinoma in Gulf region
Review Article Page 1 of 6 Status of hepatocellular carcinoma in Gulf region Kakil Ibrahim Rasul 1,2, Safaa H. Al-Azawi 1, Prem Chandra 3, Ghassan K. Abou-Alfa 4,5, Alexander Knuth 1 1 National Center
More informationHepatocellular Carcinoma
Hepatocellular Carcinoma Luis S. Marsano, MD Professor of Medicine Division of Gastroenterology, Hepatology, & Nutrition University of Louisville & Louisville VAMC 2010 Magnitude of the Problem 95% of
More informationTherapeutic Response Assessment and Endpoints in HCC
APASL HCC Conference, 2013 Cebu Therapeutic Response Assessment and Endpoints in HCC Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Surgery Chief of Hepatobiliary and Pancreatic Surgery The University
More information100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days
100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days TheraSphere [US package insert]. Surrey, UK: Biocompatibles UK Ltd,
More informationThe prognostic classification of patients with
HEPATOLOGY, VOL. 67, NO. 6, 2018 AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES HEPATOBILIARY MALIGNANCIES External Validation of the ITA.LI.CA Prognostic System for Patients With Hepatocellular
More informationComplication of Portal Hypertension: should the patients in the waiting list be treated differently?
Wilma Debernardi Venon Gastroepatologia, Az. Osp. San Giovanni Battista ditorino Complication of Portal Hypertension: should the patients in the waiting list be treated differently? Il sottoscritto dichiara
More informationPresentation, Treatment, and Clinical Outcomes of Patients With Hepatocellular Carcinoma, With and Without Human Immunodeficiency Virus Infection
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:1284 1290 Presentation, Treatment, and Clinical Outcomes of Patients With Hepatocellular Carcinoma, With and Without Human Immunodeficiency Virus Infection
More information